This investigation evaluated the feasibility of using subdermally implantable devices fabricated by nonconventional 3-dimensional printing technology for controlled delivery of ethinyl estradiol (EE 2 ). In vitro release kinetics of EE 2 and in vivo pharmacokinetics/pharmacodynamics in ovariectomized New Zealand White rabbits were carried out to study 3 implant prototypes: implant I (single-channel EE 2 distribution in polycaprolactone polymer core), implant II (homogeneous EE 2 distribution in polycaprolactone polymer matrix), and implant III (concentration-gradient EE 2 distribution in polycaprolactone and poly(dl-lactide-co-glycolide) (50:50 matrix). EE 2 was found to be released from all the implants in a nonlinear pattern with an order of implant III > implant II > implant I. The noncompartmental pharmacokinetic analysis of plasma EE 2 profiles in rabbits indicated a significant difference (p < .05) in C max , t max , and mean residence time between implant I and implants II and III, but no difference in the area under the plasma concentration time curves calculated by trapezoidal rule (AUC) among the implants. For pharmacodynamic studies, endogenous follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were observed to be suppressed following implantation of all implants, which demonstrated that a therapeutically effective dose of EE 2 had been delivered. Furthermore, the noncompartmental analysis of plasma FSH and LH profiles in rabbits showed a significant difference (p < .05) in AUC and the mean residence time between implant III and implants I and II. A good in vivo/in vitro relationship was observed between daily amounts of EE 2 released and plasma profiles of EE 2 for all implants. This relationship suggests that plasma profiles of EE 2 could be predicted from in vitro measurement of daily amount of EE 2 released. Therefore, performing in vitro drug release studies may aid in the development of an EE 2 implant with the desired in vivo release rate.
ABSTRACT
This investigation evaluated the feasibility of using subdermally implantable devices fabricated by nonconventional 3-dimensional printing technology for controlled delivery of ethinyl estradiol (EE 2 ). In vitro release kinetics of EE 2 and in vivo pharmacokinetics/pharmacodynamics in ovariectomized New Zealand White rabbits were carried out to study 3 implant prototypes: implant I (single-channel EE 2 distribution in polycaprolactone polymer core), implant II (homogeneous EE 2 distribution in polycaprolactone polymer matrix), and implant III (concentration-gradient EE 2 distribution in polycaprolactone and poly(dl-lactide-co-glycolide) (50:50 matrix). EE 2 was found to be released from all the implants in a nonlinear pattern with an order of implant III > implant II > implant I. The noncompartmental pharmacokinetic analysis of plasma EE 2 profiles in rabbits indicated a significant difference (p < .05) in C max , t max , and mean residence time between implant I and implants II and III, but no difference in the area under the plasma concentration time curves calculated by trapezoidal rule (AUC) among the implants. For pharmacodynamic studies, endogenous follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were observed to be suppressed following implantation of all implants, which demonstrated that a therapeutically effective dose of EE 2 had been delivered. Furthermore, the noncompartmental analysis of plasma FSH and LH profiles in rabbits showed a significant difference (p < .05) in AUC and the mean residence time between implant III and implants I and II. A good in vivo/in vitro relationship was observed between daily amounts of EE 2 released and plasma profiles of EE 2 for all implants. This relationship suggests that plasma profiles of EE 2 could be predicted from in vitro measurement of daily amount of EE 2 released. Therefore, performing in vitro drug release studies may aid in the development of an EE 2 implant with the desired in vivo release rate.
INTRODUCTION
Subcutaneous implants have been increasingly recognized as a useful drug delivery system that provides greater assurance of patient compliance and a better therapeutic outcome than conventional drug therapies, particularly for chronic medication [1] [2] [3] . A survey of the literature showed that numerous studies have been performed to investigate the use of polymercontrolled drug delivery systems [4] [5] [6] [7] , efficacy [8] [9] [10] , and pharmacokinetics and pharmacodynamics [11] [12] [13] of subdermal implants for the controlled delivery of drugs for long-term therapy. The science and the engineering approaches in the development of implantable therapeutic systems have been well described in the literature [14] .
The most common method for manufacturing matrixtype implants is to blend the drug with the polymers and then use a compression or injection molding technique to fabricate the device [15] . Recently, a novel 3-dimensional fabrication technology [16] [17] [18] [19] has been developed for the manufacture of biodegradable implants in a rapid, highly reproducible manner [20] . The in vitro release kinetics of polymeric drug delivery systems fabricated by this technology have been evaluated, and a complex drug delivery pattern has been demonstrated. The release of multiple drugs or multiphasic release of a single drug from the same implant may be achieved [20] . However, in vivo evaluation of implants fabricated by this technology has not been conducted to date.
*
In this investigation, 3 prototype subdermal implants using ethinyl estradiol (EE 2 ) as the model drug were fabricated using this novel 3-dimensional fabrication technology. In addition to in vitro kinetic studies, the in vivo release kinetics of EE 2 and its pharmacokinetic profiles and pharmacodynamic responses from each of the implants were conducted in ovariectomized New Zealand White rabbits to establish the in vitro/in vivo relationship. The pharmacokinetic-pharmacodynamic relationship and the effects of system design were also investigated.
MATERIALS AND METHODS

Materials
All polymers used in the fabrication of the devices were obtained from Birmingham Polymers, Inc (Birmingham, AL). Ethinyl estradiol was obtained from Spectrum Chemicals (New Brunswick, NJ). All chemicals used in the analysis were obtained from Fisher Scientific (Pittsburgh, PA).
Fabrication of Implants
All implants used in these studies were manufactured using Therics' (Princeton, NJ) proprietary 3-dimensional fabrication technology (TheriForm) [19] . Briefly, the TheriForm technology is a solid, free-form fabrication process in which objects are built in a laminated fashion (Figure 1) . Polymer (or excipient) powder is first spread on a powder bed in a thin layer. The printhead assembly then scans over the powder bed, depositing the binder droplets through a nozzle onto selected regions. Different materials may be dispensed through single or multiple nozzles as particulate matter in a liquid vehicle or as dissolved matter in a liquid carrier. In regions where the binder is printed, the powder particles are held together through a variety of material-specific interactions, creating regions consolidated by solid bridges within the 2-dimensional slice. A new layer of powder is spread after the floor of the powder bed is lowered. Information for each layer is relayed from the computer 
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(which uses a computer-aided design rendition for its instructions) and then printed. The process of powder spreading and printing is repeated until construction of the object is completed. A more thorough explanation of the TheriForm technology and its applications in drug delivery systems has been published previously [19, 20] .
Implant Designs
With the accurate spatial distribution possible with TheriForm technology, drug content and release rates can be well-defined and achieved with low variation. Using these features, 3 implant prototypes were designed and fabricated. One such design is shown in Figure 2 . This implant (implant I) comprised a single channel of EE 2 embedded in a matrix of poly-ecaprolactone (PCL; MW 100,000 Da; IV 1.0-1.3 dL/g; Tg < -60). Additionally, 2 other designs were fabricated: implant II, in which EE 2 was homogeneously distributed in a PCL matrix, and implant III, in which EE 2 was placed in a concentration gradient in a polymer matrix comprising a blend of PCL and poly(lactide-co-glycolide) (PLGA 50:50; MW 50 000 Da; IV 0.55-0.75; Tg 45°C-50°C) ( Table  1) . Each of the implants has a 1.5 ' 1.5 ' 35 mm 3 dimension and 1.8 mg of EE 2 in loading.
In Vitro Evaluations In Vitro Release Studies
Release studies for each of the implant designs (n = 6 for each) were conducted in isotonic phosphate buffer (5 mM; pH 7.4). Implants were placed in 8-mL glass vials filled with the buffer and incubated in a shaking water bath at 37°C. At predetermined time intervals, the solution in the vial was removed and replenished. The sample was filtered through a 0.22-µm filter and analyzed using the fluorospectrophotometric method.
Analytical Instrument and Methods
For the in vitro release samples, EE 2 was analyzed using a fluorospectrophotometer at an excitation wavelength of 288 nm and emission wavelength of 311 nm. A standard curve was established before each quantitative analysis. Residual drug content was analyzed using a high-performance liquid chromatography (HPLC) method. A rapid, sensitive HPLC method for determining EE 2 content in the implants was developed. A Hewlett-Packard 1100 HPLC device was used. The active component was separated from excipients on reverse-phase C8 column (Alltech, Lichrosorb RP-8, 5 m, 4.6 × 250 mm) by elution with water-acetonitrile (40:60) at a flow rate of 1 mL/min. An ultraviolet detector set at 280 nm was used. The samples were extracted with dioxane and diluted with mobile phase. The detection limit was 1 µg/mL.
In Vivo Evaluations Ovariectomized Rabbit Model
Twelve female New Zealand White rabbits, surgically ovariectomized, were purchased from Covance Research Products Inc (Denver, PA). All animals were recovered after the surgery for at least 3 weeks before the initiation of studies. The animals were housed individually in cages under environmentally controlled conditions (temperature 20°C ± 1°C, relative humidity 50%, and a 12-hour lighting cycle). These animals were fed once daily with a standard rabbit diet that is commercially available and had access to water ad libitum. The ovariectomized rabbit model was used to simulate actual postmenopausal conditions, in which natural estradiol production is suppressed.
Animal Study
On the day of implantation, the procedure was carried out as described elsewhere [21] . In brief, the hair over the lower lumbar dorsal site of each rabbit was clipped and the skin was cleaned by alcohol swab. Before implant insertion, the animals were anesthetized by subcutaneous injection of lidocaineand all apparatus and tools were sterilized. After placing each EE 2 implant inside a 10-gauge hypodermic needle, the Following the implantation, serial blood samples (~4 mL each) were drawn from the rabbits' marginal veins at 1, 2, 4, 7, 10, 14, 18, 22, 26, and 30 days and once a week thereafter for a total of 13 weeks. The blood samples were centrifuged, and plasma was immediately transferred into a vacuum tube containing NaF and then stored in a freezer at -20°C until assay of EE 2 , estradiol (E 2 ), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) was completed. A capillary GC/MSmethod, using negative ion chemical ionization with selective ion monitoring, was used to determine the plasma concentrations of EE 2 , while specific radioimmunoassays (RIAs) were used to determine the plasma levels of E 2 , FSH, and LH [22, 23] .
Three prototypes of EE 2 implants (Table 1) were administered randomly into 3 groups of rabbits (4 rabbits in each group). A total of 12 experiments were performed. The mean body weight of rabbits was ~2.5 kg at time of implantation and ~3.5 kg at completion of the 13-week implantation studies.
Pharmacokinetic Analysis
For 
Statistical Analysis
The analysis of variance (ANOVA) was used in this investigation to determine the statistical significance of the differences among the EE 2 implants for each parameter obtained from the in vitro and in vivo studies. If the result of ANOVA indicated a significant difference (p < .05), these were then, on a pairing basis, analyzed using the Student-Newman-Keuls test.
RESULTS
In Vitro Evaluations
To gain a better insight into the mechanisms underlying the controlled release of EE 2 from the subcutaneous tissue implants and their role in the systemic delivery of EE 2 , the release kinetics of EE 2 were investigated. The in vitro release profiles compared in Figure 3A indicate that all the implants released EE 2 continuously, but at nonlinear kinetics, throughout the 13-week study for implant I and for about 7 weeks for implants II and III. The release profiles were observed to tap off afterward. The maximal levels, 76% for implant II and 95% for implant III, of the incorporated EE 2 were released during the 7-week period. The daily amounts of EE 2 released from the implants were also calculated. The results compared in Figure  3B indicate that implants II and III have released a higher daily dose of EE 2 than did implant I within the first week. Then the release rates of EE 2 from implants II and III declined to the same dose range as that of implant I from week 2 to week 8, and further reduced thereafter to below the dose range for implant I until the end of the study. On the other hand, the daily dose of EE 2 released from implant I is observed to stay at a steady level for the first 4 to 5 weeks before declining gradually thereafter throughout the 13-week study. 
In Vivo Evaluations
The plasma profiles of EE 2 following the subcutaneous implantation of EE 2 implants in 3 groups of ovariectomized rabbits are compared in Figure 4 . The results indicate that plasma EE 2 concentrations reached a peak level within 4 days following the implantation, and then declined gradually toward the baseline in the following 6 weeks for implants II and III. On the other hand, implant I was observed to achieve a lower peak level of EE 2 than were implants II and III, but more steady and higher concentrations were maintained throughout the 13-week study, especially the final 6 weeks.
Pharmacokinetic parameters obtained from the noncompartmental analysis of plasma EE 2 profiles (displayed in Figure 4 ) are compared in The plasma profiles of E 2 in the 3 groups of ovariectomized rabbits, in response to the subcutaneous implantation of EE 2 -implants, were also measured by RIA. Results compared in Figure 5 appear to suggest that relatively steady plasma E 2 levels have been achieved and maintained throughout the 13-week study period. The pharmacodynamic parameters obtained from a noncompartmental analysis of the plasma E 2 profiles (displayed in Figure 5 ) are shown in Table 3 , which indicate that there are no differences in the mean values of AUC last (435, 563, and 729 ng/L × day for implants I, II, and III, respectively) and MRT last (42.9, 42.2, and 46.5 days for implants I, II, and III, respectively) among the 3 groups of EE 2 implants. The observations imply that the effect of difference in the delivery rates of EE 2 on the pharmacodynamic responses-in terms of the secretion of endogenous E 2 -in the ovariectomized rabbit model is very minimal, if any. †The results of ANOVA tests indicated a significant difference (p < .05) between implant I and implants II and III, but not between implants II and III. The differences were substantiated by pairwise comparisons using the Student-Newman-Keuls test. Cmax indicates the peak concentration observed during the dosing period; tmax, time to reach the peak concentration (Cmax); AUC, the area under the plasma concentration time curves calculated by trapezoidal rule; MRT, the mean residence time; ANOVA, analysis of variance. The plasma profiles of FSH and LH in the 3 groups of ovariectomized rabbits, in response to the subcutaneous controlled delivery of EE 2 from the various EE 2 implants, were also measured by RIA. Results compared in Figures 6A and B indicate that the EE 2 delivered has shown similar effect on the secretion of endogenous FSH and LH, as demonstrated by the similarity in the pattern of plasma profiles throughout the entire course of 13-week implantation. The plasma concentrations of FSH and LH decrease rapidly from the basal levels immediately following the implantation to the minimum in less than a week. The suppression is maintained for 6 to 12 weeks, depending on the type of implant, and then increased again. The duration of 8 suppression and the extent of rebound in FSH and LH appear to depend on the rate of EE 2 disappearance from the systemic circulation. The basal levels of FSH and LH are recovered within the 13-week study period for implant III, but may require a longer period for implants I and II.
Table 3. Comparison in Pharmacodynamic Responses of Plasma Ethinyl Estradiol (EE2) Delivered from Various EE2 Implants in Ovariectomized Rabbits
The pharmacodynamic parameters obtained from a noncompartmental analysis of the plasma FSH and LH profiles are reported in 
DISCUSSION
In Vitro Evaluations
Because of the different designs of these implants, as shown in Table 1 , the release pattern of EE 2 from the implants was found to vary ( Figure 3A) . Based on the mechanisms of bioerosion-modulated drug release reported in the literature [14] , the release of EE 2 from the various subdermal implants is essentially controlled by a combination of passive diffusion and polymer erosion from the biodegradable polymer matrix. It has been reported that implants fabricated from PCL are capable of delivering an incorporated drug for several months when a lower molecular weight polymer (eg, 30 000 Da) is used, to more than 1 year when a higher molecular weight polymer (eg, 56 000 Da) is used [25] .
On the other hand, the implants fabricated from PLGA were found to be degraded almost completely before the end of the 8-week studies [3, 5, 26] . The results appear to suggest that PGLA has a higher rate of hydrolytic degradation than does PCL. Because of slow erosion of PCL-based polymeric matrix, the release of EE 2 from implants I and II was apparently controlled primarily by the passive diffusion under a concentration gradient. Therefore, a higher release rate and a shorter delivery duration of EE 2 from implant II (with homogeneous distribution of EE 2 ) than from implant I (with a single-channel distribution of EE 2 ) was attained, as expected. Because PLGA-based polymeric matrix has a faster rate of erosion than PCLbased polymeric matrix, the release of EE 2 from implant III appeared to be controlled by a combination of the passive diffusion of EE 2 under the concentration gradient of EE 2 and the erosion of the biodegradable polymer by the hydrolysis of polymer chains. Therefore, implant III releases EE 2 at the highest rate of release and, thus, the shortest duration of delivery among the implants studied ( Figure 3A ).
In Vivo Evaluations
Following implantation of the implants, the sites of implantation were frequently checked visually. No inflammatory responses, infection, or irritation, which could be due to the administration procedure or the implant itself, were detected throughout the entire course of the 13-week studies. Moreover, the wound caused by the hypodermic needle was noted to heal within the first week after implantation. Although neither inflammation nor irritation was observed in all the rabbits treated, it was interesting to note that implants I and II appear to be more easily detected than implant III. These observations suggest that implant III might be degraded in the subcutaneous tissue at a rate faster than that of implants I and II. This finding is in good agreement with the fact that PLGA degrades by a bulk hydrolysis of its ester bonds, and is thus broken down into its constituent monomers (lactic and glycolic acids) and then excreted from the body [5] . This finding was further confirmed by the observation that implant III could not be detected or removed at the end of the study, in contrast to implants I and II. A typical picture of implant I, retrieved from the rabbits after 5-month of implantation, is displayed in Figure 7 , indicates that the structural integrity of implant I was maintained during the study period. Moreover, it is interesting to note that the time (~6 weeks after implantation) plasma FSH and LH levels took to return to baseline is similar to the time required for plasma EE 2 levels to reach the end of delivery from implant III. This agreement suggests that, in addition to the attainment of a satisfactory in vivo/in vitro relationship, a good pharmacokineticspharmacodynamic relationship has also been established for EE 2 delivered subcutaneously from implant III. A similar correlation and relationship were observed for implant II but not for implant I (possibly due to early termination of the animal study). The primary objective of applying subcutaneous implantation for drug delivery is to control the delivery of drug to subcutaneous tissue and to maintain the therapeutic effect throughout the treatment duration of interest [ 1, 2] . Implant I appeared to best achieve these goals. As shown in Figures 4 and 6 , implant I not only demonstrated a controlled release of EE 2 throughout the period of subcutaneous implantation, but also the amount of EE 2 delivered is capable of maintaining its pharmacological effect by effectively suppressing the secretion of endogenous FSH and LH. These in vivo findings have substantiated the in vitro results on the usefulness of the controlled-release subdermal implants fabricated by the 3-dimensional printing fabrication technology.
In Vivo/In Vitro Relationships
To establish the in vivo/in vitro relationship between the daily amount released and the plasma profiles of EE 2 , the results displayed in Figures 3B and 4 were compared and replotted in Figures 8A, 8B , and 8C for implants I, II, and III, respectively. A good in vivo/in vitro relationship was attained for all the implants studied. The agreement may suggest that the plasma profiles of EE 2 could be predicted by measuring the daily amount of EE 2 released from the implants by the in vitro studies. Therefore, an implant with a desired in vivo rate of EE 2 release could be developed by simply performing the in vitro drug release studies in combination with system optimization. A significant reduction in the number of animals used in the in vivo test as well as substantial savings in time and cost could be realized. 
